About Careers MedBlog Contact us

New Tools and Methods for Tuberculosis Care

by Colleen Fleiss on April 9, 2019 at 1:09 AM
Font : A-A+

New Tools and Methods for Tuberculosis Care

A new model for estimating the distribution of tuberculosis drugs in patients' lung lesions has been developed by Radojka M. Savic, of the University of California, San Francisco, and colleagues.

This week, publication of a special issue on tuberculosis (TB) begins in PLOS Medicine, advised by guest editors Richard Chaisson of Johns Hopkins University, Claudia Denkinger of the University of Heidelberg, and Mark Hatherill of the South African Tuberculosis Vaccine Institute. Last year the United Nations held a High Level Meeting on TB, where heads of state pledged to eliminate the disease by 2030.


The Special Issue opens with publication of two original research articles:

They used data on 329 plasma- and 1,362 tissue-specific drug concentrations from 9 distinct lung lesion types obtained from 15 patients (10 men, 5 women) undergoing lung resection surgery, to develop and evaluate a site-of-action mechanistic pharmacokinetic model for 7 major TB drugs (rifampin [RIF], isoniazid [INH], linezolid [LZD], moxifloxacin [MFX], clofazimine[CFZ], pyrazinamide [PZA], and kanamycin [KAN]). The researchers found that patients receiving standard doses of RIF and INH, who are at the lower range of exposure distribution, spent substantial periods (>12 h/d) below effective concentrations in hard-to-treat lesions, such as caseous lesions and cavities.

Standard doses of INH (300 mg) and KAN (1,000 mg) did not reach therapeutic thresholds in most lesions for a majority of the patient population. The investigators also found that the majority of TB drugs showed poor penetration into the cavitary lesions, leading to inadequate drug levels at the site of disease and increased risk of developing drug resistance.

The authors note that this was a small group of patients from a unique population of TB patients who failed treatment and underwent lung resection surgery. Still, the authors note that the finding that TB drugs do not penetrate equally in different tissues suggests that a patient-focused approach to optimize drug regimen to the disease extent, lesion type, and individual drug-susceptibility profiles may eventually be useful to guide selection of tailored drug regimens with improved outcomes. They provide a web-based tool to further explore this model and results at http:// saviclab.org/tb-lesion/.

In the second article, Ankur Gupta-Wright, of London School of Hygiene & Tropical Medicine, and colleagues develop a clinical risk score for identifying HIV-positive patients diagnosed with TB with an increased chance of dying within 2 months. The risk score includes 6 factors that can be measured upon hospital admission, including a urine TB diagnostic test to detect the protein lipoarabinomannan [LAM], age, sex, previous experience on antiretroviral treatment, anaemia, and ability to walk unaided. The score was derived in a cohort of 315 patients from the STAMP TB screening trial in Malawi and South Africa, and externally validated in 644 patients from 2 other studies done in South Africa, Zambia, Zimbabwe, Tanzania, and Kenya. For patients identified by the score as high-risk, the odds of dying within 2 months were about 5 times greater (odds ratio 5.3, 95% confidence interval 2.2-9.5) compared to patients classified as low-risk in the validation cohort. The authors note that this risk score depends on access to urine LAM testing, does not measure all potential predictors of mortality (e.g., TB drug resistance), and further validation in larger and diverse cohorts is necessary. However, this risk score may be able to identify patients who could benefit from enhanced clinical care, follow-up, and/or adjunctive interventions.

In addition to the research articles this week, the Special Issue includes a blog on Speaking of Medicine featuring the stories of six survivors of TB, discussing their experiences with different aspects of the TB care cascade, and how it led them to advocate at a local and global level to improve TB care.

The Special Issue will continue with further research and discussion articles appearing over the next several weeks.

Source: Eurekalert


Recommended Reading

Latest Respiratory Disease News

What Are the Lessons Learned from the Tuberculosis Vaccine Rollout?
India is left with 32 months (2025) to end tuberculosis and Nigeria is left with 92 months (2030) respectively.
 Can New Medtech Help India Fight Tuberculosis?
Globally every year tuberculosis affects more than 10 million people. India contributes to 30% of the global tuberculosis burden.
Bitter Taste Receptors May Save You from Asthma and COPD
People suffering from asthma or Chronic obstructive pulmonary disease (COPD) might one day benefit from new treatments that trigger bitter taste receptors.
Outbreak Alert: H3N2 Virus Sparks Concern as Patients Report Unusual Ear Fullness
Rising influenza cases in India have resulted in more patients reporting pneumonia-like conditions and ear fullness.
 Immune Cells in Lungs Give Protection Against Allergic Asthma
How to prevent allergic asthma? The functional reprogramming of immune cells encountering viruses gives protection against the development of allergic asthma.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Tools and Methods for Tuberculosis Care Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests